Integrated Diagnostics Holdings PLC Notice of Results (6649Y)
08 September 2022 - 1:04AM
UK Regulatory
TIDMIDHC
RNS Number : 6649Y
Integrated Diagnostics Holdings PLC
07 September 2022
Integrated Diagnostics Holdings Plc Notice of Results
7 September 2022
(London) Integrated Diagnostics Holdings ("IDH," "the Group," or
"the Company"), a leading consumer healthcare company with
operations in Egypt, Jordan, Sudan and Nigeria, will publish its r
esults for the six-month period ended 30 June 2022 on Monday, 12
September 2022 at 7am (UK).
An analyst and investor call will be hosted at 2pm (UK) | 3pm
(Egypt) on Tuesday, 13 September 2022. You can register for the
call by clicking on this link , and you may dial in using the
conference call details below:
-- Webinar ID: 928 3447 8622
-- Webinar Passcode: 651028
For more information about the event, please contact:
amr.amin@cicapital.com
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar
in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar
Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record
for quality and safety has earned the Company a trusted reputation,
as well as internationally recognised accreditations for its
portfolio of over 2,000 diagnostics tests. From its base of 520
branches as of 31 March 2022, IDH will continue to add laboratories
through a Hub, Spoke and Spike business model that provides a
scalable platform for efficient expansion. Beyond organic growth,
the Group's expansion plans include acquisitions in new Middle
Eastern, African, and East Asian markets where its model is
well-suited to capitalise on similar healthcare and consumer trends
and capture a significant share of fragmented markets. IDH has been
a Jersey-registered entity with a Standard Listing on the Main
Market of the London Stock Exchange (ticker: IDHC) since May 2015
with a secondary listing on the EGX since May 2021 (ticker:
IDHC.CA). Learn more at idhcorp.com .
The person responsible for arranging the release of this
announcement is Nancy Fahmy, Investor Relations Director at
IDH.
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGZGGLKNMGZZM
(END) Dow Jones Newswires
September 07, 2022 11:04 ET (15:04 GMT)
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Apr 2024 to May 2024
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From May 2023 to May 2024